IMMUNOHISTOCHEMISTRY, MYELOPEROXIDASE

The IHC – Myeloperoxidase (MPO) test is an immunohistochemistry-based diagnostic assay used to detect myeloperoxidase enzyme expression in tissue samples. Myeloperoxidase is an enzyme normally present in myeloid cells, particularly neutrophils and their precursors, and serves as one of the most important markers for identifying myeloid lineage cells.

This test is widely used in hematopathology to diagnose and classify acute myeloid leukemia (AML) and other myeloid neoplasms. MPO staining helps pathologists distinguish myeloid leukemias from lymphoid malignancies and accurately determine the cellular origin of abnormal blood-forming cells.

Because treatment strategies differ significantly between myeloid and lymphoid cancers, accurate lineage identification using MPO is essential for appropriate diagnosis, prognosis assessment, and therapeutic planning.

Benefits of the Test

• Helps diagnose acute myeloid leukemia (AML)
• Assists in identifying myeloid cell lineage
• Supports classification of hematological malignancies
• Differentiates myeloid from lymphoid neoplasms
• Helps guide treatment planning and prognosis evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC Myeloperoxidase test when evaluating suspected leukemia or myeloid malignancies. It is commonly used in:

• Acute myeloid leukemia (AML) diagnosis
• Myeloid sarcoma evaluation
• Bone marrow biopsy assessment
• Hematological malignancy classification
• Leukemia immunophenotyping studies
• Investigation of undifferentiated hematopoietic tumors

MPO is frequently used alongside markers such as CD34, CD117, CD68, CD43, CD61, and TdT to provide comprehensive hematopathology profiling.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a bone marrow biopsy, tissue biopsy, or surgical specimen
• No fasting is required
• No medication restrictions are generally necessary
• Previous blood counts and pathology findings may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected acute myeloid leukemia
• Individuals undergoing bone marrow evaluation
• Patients with suspected myeloid sarcoma
• Cases requiring leukemia classification
• Hematology and oncology patients requiring immunohistochemistry profiling

The IHC Myeloperoxidase test is an important diagnostic tool in hematopathology. By identifying myeloid differentiation, it helps clinicians accurately classify leukemia and other blood-related cancers, ensuring appropriate treatment and management.

Clinical Significance

Myeloperoxidase immunostaining is commonly used in the evaluation of:

• Acute myeloid leukemia (AML)
• Myeloid sarcoma
• Myeloproliferative neoplasms
• Bone marrow disorders
• Undifferentiated hematologic malignancies
• Myeloid lineage tumors

Strong MPO positivity is considered a key indicator of myeloid differentiation and is highly valuable in distinguishing AML from acute lymphoblastic leukemia (ALL).